Skip to main content
. 2015 Sep 25;6(31):31134–31150. doi: 10.18632/oncotarget.5290

Figure 1. AR-42 treatment induces CD44 downregulation in multiple myeloma cell lines.

Figure 1

A. Dendrogram of the unsupervised hierarchical clustering analysis of nCounter® GX Human Immunology assays in MM.1S cells treated with 0.1 μM AR-42 for 24 hrs. B. CD44 mRNA expression measured by qRT-PCR in RNA from MM.1S cells treated for 24 hrs with 0.1, or 0.2 μM AR-42. GAPDH was used for normalization. C. CD44 protein expression in MM.1S, H929, JJN3 and LP1 cells treated with AR42 at 0.1 and 0.2 μM, or vehicle control (Ctrl) for 24 h. GAPDH was used as a loading control. D. Flow cytometric analyses of the CD44 expression in MM.1S and LP1 cells upon 24 h treatment with AR42 (0.2 μM), SAHA (1 μM) and LBH589 (LBH; 0.01 μM). Events expressing low level of CD44 are shown as % of the total events. All experiments were performed in triplicate. E. MM.1S cells were treated with different HDACi's (0.5 μM JQ12, 1 μM SAHA, or 0.2 μM AR-42), or vehicle control (Ctrl) for 48 hrs and analyzed by western blot for the levels of CD44 protein. The same blot was also stained with anti-CD48 antibody and the results were normalized to GAPDH.